{"id":"etravirine-etr","safety":{"commonSideEffects":[{"rate":"17","effect":"Rash"},{"rate":"9","effect":"Nausea"},{"rate":"8","effect":"Diarrhea"},{"rate":"7","effect":"Headache"},{"rate":"5","effect":"Vomiting"},{"rate":"5","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":{"setId":"ea3856f6-fedf-ee88-e053-2a95a90a33ce","title":"ETRAVIRINE TABLET [AVKARE]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Etravirine inhibits HIV-1 reverse transcriptase through a non-competitive binding mechanism, preventing the enzyme from synthesizing viral DNA from the viral RNA genome. This blocks HIV replication and reduces viral load in infected individuals. It is particularly effective against certain drug-resistant HIV strains due to its unique binding interactions with the reverse transcriptase enzyme.","oneSentence":"Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds to HIV-1 reverse transcriptase and blocks its ability to convert viral RNA into DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:52:23.249Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-experienced patients with NNRTI resistance"},{"name":"HIV-1 infection in antiretroviral-experienced adults"}]},"trialDetails":[{"nctId":"NCT00980538","phase":"PHASE3","title":"TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Sciences Ireland UC","startDate":"2009-12-09","conditions":"HIV Infections, HIV-1","enrollment":180},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT04630002","phase":"PHASE1","title":"Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-10-28","conditions":"HIV Infections","enrollment":54},{"nctId":"NCT05506605","phase":"PHASE4","title":"Switch Strategy From Etravirine (ETR) to Doravirine (DOR) in Virologically-Suppressed HIV-1 Infected Adults With ETR-Resistance","status":"UNKNOWN","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-12-12","conditions":"HIV-1-infection","enrollment":12},{"nctId":"NCT01504841","phase":"PHASE1, PHASE2","title":"Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-03-14","conditions":"HIV Infections","enrollment":26},{"nctId":"NCT02212379","phase":"PHASE2","title":"Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2015-01","conditions":"HIV-1 Infection","enrollment":170},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT01641367","phase":"PHASE4","title":"A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-02-22","conditions":"HIV-1 Infection","enrollment":545},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT02818348","phase":"PHASE1","title":"Clinical Trial to Evaluate Drug-drug Interactions Between Darunavir/Cobicistat and Etravirine in Hiv- Infected Patients","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2016-06","conditions":"HIV-1 Infection","enrollment":30},{"nctId":"NCT00855413","phase":"PHASE4","title":"HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and Etravirine","status":"TERMINATED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2009-03","conditions":"Acute HIV Infection, HIV Infections","enrollment":15},{"nctId":"NCT02063360","phase":"PHASE1","title":"DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-02-01","conditions":"Infection, Human Immunodeficiency Virus","enrollment":42},{"nctId":"NCT01422330","phase":"PHASE4","title":"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Etravirine Administered in Combination With Other Antiretroviral Agents in Antiretroviral Treatment-Experienced HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2011-09","conditions":"Human Immunodeficiency Virus (HIV) Infection","enrollment":211},{"nctId":"NCT01625169","phase":"NA","title":"Etravirine Pharmacokinetics and HIV Viral Load in Breast Milk and Plasma","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2010-04","conditions":"HIV","enrollment":9},{"nctId":"NCT01254656","phase":"PHASE2","title":"A Long Term Safety Study Of Lersivirine For The Treatment Of HIV-1 Infection In Subjects Who Have Completed Treatment With Lersivirine In Studies A5271015 And A5271022","status":"TERMINATED","sponsor":"Pfizer","startDate":"2011-02","conditions":"HIV-1","enrollment":108},{"nctId":"NCT01199939","phase":"PHASE2","title":"A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients","status":"COMPLETED","sponsor":"Tibotec, Inc","startDate":"2010-05","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":54},{"nctId":"NCT00896051","phase":"PHASE2","title":"TMC125-TiDP2-C238: An Exploratory Pharmacokinetics, Safety and Anti-HIV Activity Study of Etravirine (ETR) When Given With Boosted Atazanavir (ATV/Rtv) at Two Different Doses and 1 Nucleoside Reverse Transcriptase Inhibitor (NRTI) in Treatment Experienced HIV Patients","status":"COMPLETED","sponsor":"Janssen R&D Ireland","startDate":"2009-08","conditions":"HIV Infections, Acquired Immunodeficiency Syndrome","enrollment":50},{"nctId":"NCT00128830","phase":"PHASE2","title":"A Study With TMC125 in Human Immunodeficiency Virus (HIV) Type 1 Infected Patients, Who Were Treated With TMC125 Arm in a Sponsor-Selected TMC125 Study","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2005-06","conditions":"Human Immunodeficiency Virus Type 1","enrollment":211},{"nctId":"NCT01876966","phase":"PHASE1","title":"Interaction Between Etravirine or Darunavir/Ritonavir and Artemether / Lumefantrine","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2011-03","conditions":"HIV","enrollment":33},{"nctId":"NCT00903682","phase":"PHASE2","title":"A Clinical Trial Comparing the Tolerability of Etravirine to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Treatment-naive HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2009-06","conditions":"HIV Infection, HIV, Acquired Immunodeficiency Syndrome","enrollment":157},{"nctId":"NCT01090648","phase":"PHASE1","title":"TMC125HIV1083 - Swallowability of Uncoated 200 mg Etravirine Tablets in HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2010-03","conditions":"HIV-Infections","enrollment":49},{"nctId":"NCT01336829","phase":"PHASE1","title":"TMC125IFD1001 - Drug-Drug Interaction of Etravirine With Telaprevir and TMC278 With Telaprevir.","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2011-03","conditions":"Hepatitis C, HIV","enrollment":33}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TMC125","Intelence"],"phase":"marketed","status":"active","brandName":"Etravirine (ETR)","genericName":"Etravirine (ETR)","companyName":"ViiV Healthcare","companyId":"viiv-healthcare","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds to HIV-1 reverse transcriptase and blocks its ability to convert viral RNA into DNA. Used for HIV-1 infection in treatment-experienced patients with NNRTI resistance, HIV-1 infection in antiretroviral-experienced adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}